Technology | Radiation Therapy | August 01, 2016

Magphan RT Offers Integrated MR QA System for Radiotherapy

Magphan RT, MR QA radiotherapy

The Magphan RT for MR QA in radiotherapy.

July 31, 2016 — The Phantom Laboratory and Image Owl announce the introduction of Magphan RT for MR QA in radiotherapy. Magphan RT measures the key performance measurements of magnetic resonance (MR) imagers used in radiotherapy planning and guidance. The system consists of a modular, easy-to-handle phantom with automated software to analyze and track performance.

It has become increasingly important to quantify key parameters such as geometric distortion in MR images as they become increasingly used in radiotherapy. The Magphan RT phantom measures distortion with precisely position spheres spaced throughout the phantom volume. Measured and known positions are compared by the analysis software to produce a three dimensional distortion map.

The Magphan RT phantom large size configuration consists of self-contained top and bottom modules that fit together precisely. An optional center module can be placed between the top and bottom modules to produce a super size configuration. This modular design provides measurement over the range of torso sizes commonly encountered in clinical practice while ensuring that the phantom can be handled by a single medical physicist or therapist without special equipment.

The Magphan RT measures a number of important MR image characteristics that can indicate system degradation or failure. These include distortion, uniformity, resolution, slice thickness and signal to noise ratio.

The included analysis service provided by Image Owl’s Total QA is accessible on any web enabled device and requires no installation. The service analyzes, tracks, presents and stores  all the data associated with Magphan RT.

For more information: www.phantomlab.com

Related Content

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
Mirion Showcases Instadose2 Wireless Dual Detector Dosimeter at AAPM and AHRA
News | Radiation Dose Management | July 15, 2019
Featuring dual detectors, the Instadose2 dosimeter addresses international requirements for independent deep [Hp(10)]...
Example of an intentionally truncated CT image

Figure 1: Example of an intentionally truncated CT image. The truncation percentage was calculated as the ratio of the patient border touching the field of view to the total patient border (red/(read+blue)). Image courtesy of Qaelum.

Feature | Radiation Dose Management | July 15, 2019 | Niki Fitousi, Ph.D., and An Dedulle
One of the main benefits of a radiation dose management system is the possibility to automatically generate alerts when...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Fluke Biomedical Introduces RaySafe 452 Survey Meter
Technology | Radiation Dose Management | July 11, 2019
Radiation measurement often requires different devices for varying applications, adding to the cost and complexity of...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...